Addex Therapeutics Ltd. filings document a foreign private issuer and ADR-linked clinical-stage biotechnology company focused on small-molecule allosteric modulators. Form 6-K reports furnish press releases, financial results, interim condensed consolidated financial statements, MD&A, iXBRL exhibits, and risk-factor updates incorporated into Form F-3 and Form S-8 registration statements.
The disclosures cover pipeline programs such as GABAB PAM candidates, mGlu receptor modulators, ADX71149, and Neurosterix-related NTX-253, along with collaboration and licensing arrangements, strategic investments, cash resources, governance, equity-plan registrations, and foreign-issuer reporting under Form 20-F.
Addex Therapeutics Ltd. appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and a member of Executive Management. Mikhail Kalinichev is stepping down as Head of Translational Science to focus on a similar role at Neurosterix. Rocher has more than 30 years of drug discovery and development experience and returns after retiring from his Head of Pharmaceutical Development role at Neurosterix, which he began in 2024.
Addex describes dipraglurant as a Phase 2-ready asset under evaluation for future development in brain injury recovery. Its GABAB PAM candidate for substance use disorders has completed IND-enabling studies, while a second GABAB PAM program for chronic cough is ready to start them. Addex also holds a 20% equity interest in private spin-out Neurosterix US Holdings LLC.
Addex Therapeutics Ltd. reported a CHF 3.456 million net loss for the six months ended June 30, 2026, compared with CHF 3.314 million a year earlier. Cash and cash equivalents were CHF 767,328 at June 30, 2026, versus CHF 1.639 million at December 31, 2025; operating activities used CHF 1.234 million during the half-year, compared with CHF 1.019 million a year earlier.
Management expects cash at issuance to fund operations and obligations through the fourth quarter of 2027, while stating that a material uncertainty raises substantial doubt about the Group’s ability to continue as a going concern for one year from issuance. It says future viability depends on raising additional capital or securing collaboration agreements.
From July 1 to August 25, Addex sold 52,970,533 shares at an average CHF 0.043 per share for CHF 2.3 million in gross proceeds. On September 25, Indivior terminated its license agreement following its announced merger with Supernus Pharmaceuticals, returning the GABAB PAM program and related intellectual property. Addex says the program completed IND-enabling studies; plans to seek Phase 1 entry are subject to funding or a development partner.
Addex Therapeutics Ltd. regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited. The collaboration’s termination gives Addex full ownership of the returned development candidate and freedom to pursue indications beyond those originally contemplated. The return followed Indivior’s rationalization of its research and development activities.
Addex said the returned candidate is for substance use disorders and that its wholly owned GABAB PAM candidate for chronic cough is a separate program. It is evaluating strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering. Addex also described dipraglurant as a Phase 2-ready asset under evaluation for future development in brain injury recovery.
Addex Therapeutics Ltd. (ADXN) reported that its principal accounting officer, Lenaic Nathanael Teyssedou, had multiple existing stock options adjusted on September 2, 2026. Several option awards previously carrying exercise prices including $0.160, $0.053, and $0.062 per share were reported as dispositions to the issuer and corresponding acquisitions of replacement options with an exercise price of $0.032 per share. All other terms of the options, including their original exercise and expiration dates, remain unchanged, and the transactions are described as exempt under Rule 16b-6(d) and Rule 16b-3.
Addex Therapeutics Ltd. (ADXN) reported administrative equity-compensation changes for officer Mikhail Kalinichev on September 2, 2026. The company recorded the disposition to the issuer and regrant of 200,000 stock options with the exercise price reduced from $0.062 to $0.032 per share, and reflected a related repricing for 306,765 shares previously acquired under a deferred strike price payment plan. Footnotes state all other option and plan terms remain unchanged and that the transactions were exempt under specified Exchange Act rules.
Addex Therapeutics Ltd. (ADXN) director Jason Raleigh Nunn reported compensation-related adjustments on September 2, 2026 with no net change in his positions. He returned and simultaneously re-received 219,561 shares of Common Stock and 50,000 stock options, reflecting the Remuneration Committee’s decision to reprice the related strike and exercise prices to $0.032 per share while leaving all other terms unchanged. No Rule 10b5-1 trading plan is reported.
Addex Therapeutics Ltd. (ADXN) reports that director and chief medical officer Roger Mills had existing equity awards economically repriced on September 2, 2026. The exercise/strike price on 392,837 shares of common stock acquired via prior option exercises and on related stock options over 50,000 shares was reduced to $0.032 per share following a Remuneration Committee decision, with all other terms unchanged. The paired dispositions and acquisitions on the Form 4 reflect this repricing and are reported as exempt under Rule 16b-6(d) and Rule 16b-3, with U.S. dollar amounts converted from Swiss francs at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
Addex Therapeutics Ltd. (ADXN) director Isaac Manke reported repricing equity incentives on September 2, 2026. An option covering 50,000 common shares and deferred strike obligations on 219,561 previously acquired shares were reset to an exercise or strike price of $0.032 per share, with all other terms unchanged and no net change in the number of shares or options held. These actions are described as exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act and were not made under a Rule 10b5-1 trading plan.
Addex Therapeutics Ltd. (ADXN) director Lawton Vincent Michael reported a repricing of equity incentives on September 2, 2026. Existing options for 501,598 shares of common stock were surrendered and a replacement option for the same 501,598 shares was granted, reducing the exercise price from $0.062 to $0.032 per share. In addition, 2,507,487 common shares previously acquired under a deferred strike price payment plan remain outstanding, with the strike price on all related units similarly reduced to $0.032. The company states that all other terms of the options and plan are unchanged and that these transactions are exempt under specified Exchange Act rules. No Rule 10b5-1 trading plan is reported.
Addex Therapeutics Ltd. (ADXN) reported that director Raymond George Hill had paired administrative transactions on September 2, 2026 to reflect repricing of previously granted equity awards. A total of 1,365,532 shares of common stock and options over 273,107 shares were recorded as dispositions to the issuer and simultaneous grants at a reduced exercise price of $0.032 per share, while all other terms of the plans and options remained unchanged. No Rule 10b5-1 trading plan is reported.